Biocardia Inc SEC Filings

Insider purchase reported for BioCardia, Inc. (BCDA). Peter Altman, the company's President, CEO and a director, purchased 48,000 shares of common stock at $1.25 per share on 09/19/2025 through a public offering that closed that day, and received 48,000 warrants exercisable at $1.25 expiring 09/20/2027. After the transaction Mr. Altman beneficially owned 216,762 shares of common stock and 143,612 derivative securities (warrants/options) on a direct basis. The Form 4 was signed under power of attorney on 09/23/2025.

BioCardia, Inc. filed an 8-K to report that it has had a positive preliminary clinical consultation with Japan’s Pharmaceutical and Medical Devices Agency (PMDA) regarding the CardiAMP Heart Failure Trial results previously provided to the agency.

The meeting was held to prepare for a formal clinical consultation on whether the trial data will be acceptable for submission of an application for product approval in Japan. BioCardia also furnished the related press release as an exhibit to this report.

BioCardia, Inc. filed an 8-K to report that it has had a positive preliminary clinical consultation with Japan’s Pharmaceutical and Medical Devices Agency (PMDA) regarding the CardiAMP Heart Failure Trial results previously provided to the agency.

The meeting was held to prepare for a formal clinical consultation on whether the trial data will be acceptable for submission of an application for product approval in Japan. BioCardia also furnished the related press release as an exhibit to this report.

Lincoln Alternative Strategies LLC reported beneficial ownership of 800,000 shares of BioCardia, Inc. common stock, representing 7.54% of the outstanding shares based on 10,608,734 shares outstanding as of September 19, 2025. The filing lists sole voting and dispositive power over all 800,000 shares and indicates the holder is organized in Delaware. The filing includes a certification that the securities were not acquired to change or influence control of the issuer. Contact and address details for the issuer and filer are provided in the statement.

Lincoln Alternative Strategies LLC reported beneficial ownership of 800,000 shares of BioCardia, Inc. common stock, representing 7.54% of the outstanding shares based on 10,608,734 shares outstanding as of September 19, 2025. The filing lists sole voting and dispositive power over all 800,000 shares and indicates the holder is organized in Delaware. The filing includes a certification that the securities were not acquired to change or influence control of the issuer. Contact and address details for the issuer and filer are provided in the statement.

BioCardia, Inc. completed a registered offering on September 19, 2025, selling 4,800,000 shares of common stock together with warrants to purchase up to 4,800,000 shares at a combined price of $1.25 per share and warrant, generating approximately $6.0 million in gross proceeds. Certain directors and executive officers purchased 734,400 shares and warrants for roughly $0.9 million. The company expects net proceeds of about $5.1 million after placement agent fees and offering expenses. Each warrant is exercisable at $1.25, immediately exercisable, and expires September 20, 2027, subject to customary anti-dilution adjustments and beneficial ownership exercise limits (default 4.99% or elective 9.99% with notice). The Purchase Agreements include customary representations, indemnities and closing conditions, and contain lock-up and variable-rate transaction restrictions through November 18, 2025 and March 19, 2026, respectively, which the placement agent may waive.

BioCardia, Inc. completed a registered offering on September 19, 2025, selling 4,800,000 shares of common stock together with warrants to purchase up to 4,800,000 shares at a combined price of $1.25 per share and warrant, generating approximately $6.0 million in gross proceeds. Certain directors and executive officers purchased 734,400 shares and warrants for roughly $0.9 million. The company expects net proceeds of about $5.1 million after placement agent fees and offering expenses. Each warrant is exercisable at $1.25, immediately exercisable, and expires September 20, 2027, subject to customary anti-dilution adjustments and beneficial ownership exercise limits (default 4.99% or elective 9.99% with notice). The Purchase Agreements include customary representations, indemnities and closing conditions, and contain lock-up and variable-rate transaction restrictions through November 18, 2025 and March 19, 2026, respectively, which the placement agent may waive.

BioCardia is conducting a best-efforts primary offering of 4,800,000 shares of common stock, each sold together with a warrant to buy one additional share, at a combined price of $1.25 per share-and-warrant unit. Gross proceeds are expected to be $6.0 million, with approximately $5.1 million in net proceeds after fees and expenses if all securities are sold. The company expects to use the cash mainly for working capital and to advance its cell therapy programs and delivery partnering business.

After the offering, BioCardia expects 10,608,734 shares of common stock to be outstanding, excluding warrant exercises. The raise would move stockholders’ equity from a deficit to positive $3.2 million, helping address Nasdaq’s minimum equity requirement, and is expected to fund operations at current burn levels into the second quarter of 2026, though additional capital will still be needed.

BioCardia is conducting a best-efforts primary offering of 4,800,000 shares of common stock, each sold together with a warrant to buy one additional share, at a combined price of $1.25 per share-and-warrant unit. Gross proceeds are expected to be $6.0 million, with approximately $5.1 million in net proceeds after fees and expenses if all securities are sold. The company expects to use the cash mainly for working capital and to advance its cell therapy programs and delivery partnering business.

After the offering, BioCardia expects 10,608,734 shares of common stock to be outstanding, excluding warrant exercises. The raise would move stockholders’ equity from a deficit to positive $3.2 million, helping address Nasdaq’s minimum equity requirement, and is expected to fund operations at current burn levels into the second quarter of 2026, though additional capital will still be needed.

BioCardia, Inc. filed a Form 8-K to report that on September 18, 2025 it issued a press release announcing the pricing of a public offering involving its common stock and warrants. The filing presents this as a Regulation FD disclosure, meaning the company is sharing this capital markets update broadly with investors. The press release is included as Exhibit 99.1, along with an Inline XBRL cover page data file listed as Exhibit 104.

BioCardia, Inc. filed a Form 8-K to report that on September 18, 2025 it issued a press release announcing the pricing of a public offering involving its common stock and warrants. The filing presents this as a Regulation FD disclosure, meaning the company is sharing this capital markets update broadly with investors. The press release is included as Exhibit 99.1, along with an Inline XBRL cover page data file listed as Exhibit 104.

BioCardia, Inc. filed a Form 8-K to report that on September 18, 2025 it issued a press release announcing the pricing of a public offering involving its common stock and warrants. The filing presents this as a Regulation FD disclosure, meaning the company is sharing this capital markets update broadly with investors. The press release is included as Exhibit 99.1, along with an Inline XBRL cover page data file listed as Exhibit 104.

BioCardia, Inc. filed a Form 8-K to report that on September 18, 2025 it issued a press release announcing the pricing of a public offering involving its common stock and warrants. The filing presents this as a Regulation FD disclosure, meaning the company is sharing this capital markets update broadly with investors. The press release is included as Exhibit 99.1, along with an Inline XBRL cover page data file listed as Exhibit 104.

BioCardia, Inc. filed a current report describing a communication about one of its clinical programs. The company furnished a press release announcing primary endpoint results from the open label roll-in cohort of its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The press release is included as Exhibit 99.1 and is treated as furnished, not filed, under securities law.

BioCardia, Inc. filed a current report describing a communication about one of its clinical programs. The company furnished a press release announcing primary endpoint results from the open label roll-in cohort of its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The press release is included as Exhibit 99.1 and is treated as furnished, not filed, under securities law.

BioCardia, Inc. filed a current report describing a communication about one of its clinical programs. The company furnished a press release announcing primary endpoint results from the open label roll-in cohort of its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The press release is included as Exhibit 99.1 and is treated as furnished, not filed, under securities law.

BioCardia, Inc. filed a current report describing a communication about one of its clinical programs. The company furnished a press release announcing primary endpoint results from the open label roll-in cohort of its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The press release is included as Exhibit 99.1 and is treated as furnished, not filed, under securities law.

BioCardia, Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the original registration statement unchanged and focuses on updating and organizing the exhibit list, including agreements related to prior mergers, equity incentive plans, various securities purchase and warrant agreements, indemnification and change of control arrangements for executives, leasing arrangements, and at-the-market and other offering agreements with financial firms. The filing also includes legal opinions, auditor consents, and technical XBRL documents, and is signed by the President and Chief Executive Officer and the Chief Financial Officer, along with the company’s directors under a power of attorney.

BioCardia, Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the original registration statement unchanged and focuses on updating and organizing the exhibit list, including agreements related to prior mergers, equity incentive plans, various securities purchase and warrant agreements, indemnification and change of control arrangements for executives, leasing arrangements, and at-the-market and other offering agreements with financial firms. The filing also includes legal opinions, auditor consents, and technical XBRL documents, and is signed by the President and Chief Executive Officer and the Chief Financial Officer, along with the company’s directors under a power of attorney.

BioCardia, Inc. is registering up to 2,800,000 shares of common stock, up to 2,800,000 pre-funded warrants, up to 2,800,000 common warrants, and the shares of common stock issuable upon exercise of those warrants in a best efforts public offering. Each share or pre-funded warrant will be sold together with one common warrant, at an assumed combined public offering price of $2.27. The company expects net proceeds of about $5.3 million if all securities are sold, and estimates that, with current quarterly cash use of roughly $1.6 million, this funding would support operations into the second quarter of 2026.

BioCardia is a clinical-stage developer of bone marrow–derived cell and cell‑derived therapies for heart failure, chronic myocardial ischemia, and acute respiratory distress syndrome. The company is currently not in compliance with Nasdaq’s $2.5 million minimum stockholders’ equity rule and has been granted until September 29, 2025 to regain compliance. The offering is highly dilutive, carries no minimum raise or escrow, and involves speculative short‑dated warrants whose value depends on future stock price and stockholder approval in certain cases.